Evidence map›Paper›PMID 40427211›Full record

ReviewCancers2025

Active Surveillance in Non-Muscle Invasive Bladder Cancer: A Systematic Review.

Míriam Campistol, Fernando Lozano, Albert Carrion, Carles Xavier Raventós, Juan Morote, Enrique Trilla

Abstract readReview
In one paragraph

Review in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Observational
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Míriam CampistolDepartment of Urology, Vall d'Hebron Hospital, Passeig de la Vall d'Hebron 119, 08035 Barcelona, Spain.
Fernando LozanoDepartment of Urology, Vall d'Hebron Hospital, Passeig de la Vall d'Hebron 119, 08035 Barcelona, Spain.ORCID 0000-0001-9513-0614
Albert CarrionDepartment of Urology, Vall d'Hebron Hospital, Passeig de la Vall d'Hebron 119, 08035 Barcelona, Spain.ORCID 0000-0002-4639-1532
Carles Xavier RaventósDepartment of Urology, Vall d'Hebron Hospital, Passeig de la Vall d'Hebron 119, 08035 Barcelona, Spain.
Juan MoroteDepartment of Urology, Vall d'Hebron Hospital, Passeig de la Vall d'Hebron 119, 08035 Barcelona, Spain.
Enrique TrillaDepartment of Urology, Vall d'Hebron Hospital, Passeig de la Vall d'Hebron 119, 08035 Barcelona, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer is the ninth most common cancer globally, with most cases classified as non-muscle-invasive bladder cancer (NMIBC). While transurethral resection of the bladder tumor (TURBT) remains the gold-standard treatment, its complications, high recurrence rates, and economic burden have prompted interest in alternative strategies like active surveillance (AS) for low-grade and low-grade NMBIC recurrences. AS minimizes surgical interventions and patient burden, but lacks standardized protocols for inclusion criteria and follow-up schedules. Most studies suggest intensive monitoring during the first year, with criteria often based on tumor size, number, and grade. ACQUISITION OF EVIDENCE: A comprehensive literature search was conducted in December 2024 using Pubmed, Cochrane, and Trip databases to identify studies on AS for low-grade NMBIC recurrences. Only English studies were included, with Boolean operators used to refine the search. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines and the Population, Intervention, Comparison and Outcomes (PICO) selection criteria were followed. The Newcastle-Ottawa quality assessment scale was used to analyze the quality of the included studies. EVIDENCE SYNTHESIS: This systematic review included 11 studies evaluating AS for NMIBC. Early studies, such demonstrated AS as a feasible alternative to TURBT, with low progression rates. Subsequent research confirmed its safety in selected patients, with tumor growth and positive cytology being the main reasons for intervention. More recent investigations, further supported AS as a viable strategy, highlighting the low risk of stage and grade progression and its potential to reduce surgical interventions.

conclusionsAS may be considered an alternative approach for low-risk NMIBC recurrences. However, there is need for prospective studies and personalized approaches to optimize AS, addressing follow-up strategies, inclusion criteria and progression thresholds.

Indexed as

active surveillancecystoscopyexpectant managementnon-muscle invasive bladder cancerTURBT

Identifiers

PMID40427211
PMCPMC12110289

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.